Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Post Severe Acute Kidney Injury Survivors
NCT05360615Phase 1Active, not recruiting
- Sponsor
- Chulalongkorn University
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute kidney injury (AKI) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Major Adverse Kidney Events at 365 days. Started Jul 2022; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05360615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360615.